According to FutureWise analysis, the Alzheimer’s disease diagnostic market in 2025 is US$8.83 billion, and is expected to reach US$19.25 billion by 2033 at a CAGR of 10.23%. The Alzheimer's disease diagnostic market is experiencing steady growth, driven by the increasing global prevalence of dementia and greater awareness of the importance of early detection. Advances in biomarker-based diagnostics, neuroimaging technologies, and AI-enabled cognitive assessment tools are improving both the accuracy and speed of diagnoses. Additionally, increased research and development investments, along with supportive healthcare policies, are facilitating the adoption of innovative diagnostic solutions.The aging global population and the rising number of dementia cases worldwide primarily fuel the robust growth in this sector. Innovations in biomarker testing, neuroimaging technologies, and blood-based diagnostic tools are significantly enhancing the capabilities for early detection.

Furthermore, the market expansion is supported by increasing healthcare expenditures, growing awareness of cognitive health, and regulatory approvals for new diagnostic solutions.Currently, North America leads the market, while the Asia-Pacific region is emerging as the fastest-growing area, driven by improvements in healthcare infrastructure and an aging population.Alzheimer's disease is a neurodegenerative disorder that begins with mild memory loss and progressively worsens over time. Initially, symptoms manifest as minor memory issues, but they eventually lead to a decline in social interaction and communication skills. This incurable disease has a long preclinical period and follows a progressive course, significantly impacting an individual’s ability to perform daily activities. In most cases, symptoms first appear in individuals' mid-60s; however, early-onset Alzheimer's, which occurs between a person's 30s and mid-60s, is relatively rare. Alzheimer's disease is the most common form of dementia among older adults.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Alzheimer’s Disease Diagnostic Market  trends that shall affect the overall market growth.

Request a Free Sample @

https://www.futurewiseresearch.com/contact.aspx?rpt=10644&type=requestsample

By Product Type

  • Brain Imaging
  • CFS Test for Alzheimer's Disease

By Type

  • Early-Onset
  • Late-Onset
  • Familial

By End-Use

  • Hospitals
  • Specialty Clinics/ Diagnostic Centers
  • Ambulatory Surgical Centers
  • Academic and Research Institutes

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Competitive Landscape in Alzheimer’s Disease Diagnostic Market :

  • TauRx
  • Alector LLC
  • Eli Lilly and Company
  • Treventis Corporation
  • Neuro-Bio Ltd
  • Accera, Inc.
  • Cognition Therapeutics Inc.
  • Johnson and Johnson
  • F. Hoffmann-La Roche Ltd
  • Quanterix
  • Sysmex
  • Novartis AG
  • Allergan PLC
  • C2N Dignostics
  • Randox Bioscience
  • GE Healthcare
  • MAGQU CO. LTD.
  • Hitachi

Recent developments by key players in the Alzheimer’s Disease Diagnostic Market :

GE Healthcare

  • In June 2025, the FDA expanded the approval of Vizamyl (flutemetamol F-18) PET imaging to include quantitative measurements of amyloid and treatment monitoring. This enables clinicians to track changes in amyloid plaque more objectively during therapy.
  • Their MIM software for amyloid PET scans received 510(k) clearance in September 2024, enabling standardized Centiloid scaling, which enhances scan consistency and interpretation.

TauRx

  • After completing the Phase III LUCIDITY trials, TauRx submitted HMTM, a tau aggregation inhibitor, for regulatory approval in the UK in early 2025. This submission marks a significant milestone in the development of tau-targeting diagnostics and therapies.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=10644&license=multi

**Objectives of this Study: **

  1. To provide a comprehensive analysis of the Alzheimer’s Disease Diagnostic Market By Type, By Application, By End User and By Region.
  2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
  3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
  4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

  • We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
  • The customization services offered are free of charge with the purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com